Product name: Cabazitaxel

Synonyms:TXD-258;(αR,βS)-β-[[(1,1-DiMethylethoxy)carbonyl]aMino]-α-hydroxybenzenepropanoicAcid(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-5-oxo-7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-ylEster

CAS No:183133-96-2

Molecular formula:C45H57NO14

Molecular Weight:835.93

Appearance:white powders

Melting point 180 °C

Boiling point 870.7±65.0 °C(Predicted)

Density 1.31

Cabazitaxel is a microtubule inhibitor, which is suitable for combination with prednisone or prednisolone in the treatment of patients with hormone refractory metastatic prostate cancer who were previously treated with docetaxel. In the whole treatment process, the chemical book has achieved more accurate treatment. It works by destroying the microtubule network, which is essential for mitosis and interphase cell function, and causes the inhibition of cell division and cell death. Cabataxel jevtana has been shown to inhibit cell division and tumor cell proliferation by binding and stabilizing tubulin, a protein in the microtubule that provides a cytoskeleton to maintain cell shape.